Respiri signs EAS Advisors to accelerate US market expansion
Respiri launched in the US in December last year – nine months ahead of schedule.
Asthma management specialist Respiri (ASX: RSH) has signed a deal with US boutique firm EAS Advisors LLC to accelerate its expansion into the North American market.
Respiri, which develops solutions to improve the management of chronic and costly respiratory disorders, made its US market debut in December through select remote patient monitoring (RPM) partner companies, which have established relationships with local payors, physicians, hospitals and accountable healthcare organisations.
The US market move was nine months ahead of Respiri’s original schedule.
The company intends to leverage the RPM CPT (current procedural terminology) reimbursement codes, which its wheezo respiratory aid qualifies for, allowing US physicians to provide the device to monitor patient management in real time.
RPM respiratory services are expected to result in reduced exacerbations and hospitalisations, which can become a considerable health and financial burden across the board.
Respiri chief executive officer and managing director Marjan Mikel said the medical industry’s response to wheezo had been positive due to the simplicity of the solution and because it provides physicians with the market’s first real RPM solution in respiratory medicine.
US growth and expansion
New York-based EAS provides international companies with access to US industry contacts to enhance their growth and expansion.
Founded in 2008, the firm’s advisory services cover institutional market engagement, equity and debt raising, and mergers and acquisitions and capital markets.
Principal and founder Edward Sugar has worked for US-based Jeffries & Co in the area of international equity sales and trading, and in Australia as a personal and private advisor to business magnate Solomon Lew and his associated companies.
The Wall Street financier has been instrumental in introducing clinical-stage pharmaceutical companies to US banks and institutions previously.
Guiding Respiri
Mr Sugar said he was looking forward to guiding Respiri through US markets.
“After reviewing the business plans Respiri has for the US, we are confident in the opportunity,” he said.
“We are looking forward to working with the company’s experienced and knowledgeable management team as they roll out the wheezo product and technology to this new market.”
Mr Mikel said the company was keen to work with EAS and Mr Sugar.
“We have seen the impressive work EAS has done with other ASX-listed companies in bringing them to a wider US audience and we are delighted to be working with the firm as we continue our growth in that market,” he said.